Lariocidin: The Soil-Discovered Antibiotic That Could Change How We Fight Drug-Resistant Bacteria

Researchers at McMaster University in Canada, working in collaboration with scientists at the University of Illinois Chicago, have discovered a new class of antibiotics for the first time in nearly three decades. The molecule, called lariocidin, was published in the journal Nature on March 26, 2025, and represents what researchers describe as a significant advance in the fight against antimicrobial resistance (AMR), one of the most urgent public health threats of our era.

The story of lariocidin's discovery begins in unremarkable circumstances: a soil sample collected from a backyard in Hamilton, Ontario, by a member of the research team. The sample was cultivated in the laboratory for approximately one year, a deliberate slow-growth method designed to allow even the slowest-growing bacterial species to emerge. From within that slow-grown bacterial community, a species called Paenibacillus was found to produce a substance with potent antibiotic activity against other bacteria, including strains that resist existing drugs.

What makes lariocidin particularly significant is not just its activity but its mechanism. It is a lasso peptide, a class of molecules defined by their distinctive knotted, lasso-like molecular structure. When the McMaster team analyzed how lariocidin kills bacteria, they found it binds to the bacterial ribosome, specifically to a site within the small ribosomal subunit that no previously known antibiotic has targeted. By binding at this novel site, lariocidin prevents bacteria from correctly reading messenger RNA and producing the proteins they need to grow and survive. Because lariocidin acts at an entirely new binding site, it is not susceptible to the resistance mechanisms that bacteria have evolved to defeat drugs targeting nearby, previously exploited sites.

The experimental results were striking across multiple dimensions. In laboratory tests, lariocidin demonstrated potent activity against both gram-positive and gram-negative bacteria, including strains identified by the WHO as priority pathogens due to their multi-drug resistance profiles. It showed strong activity against Acinetobacter baumannii, a dangerous and notoriously resistant pathogen. In mouse infection models, 100 percent of mice treated with lariocidin survived 48 hours after treatment, while none of the untreated control mice survived that period. The molecule also showed no toxicity to human cells.

The scale of the problem lariocidin addresses is difficult to overstate. According to the WHO, antimicrobial resistance contributes to approximately 4.5 million deaths globally each year, and projections suggest that unaddressed AMR could kill 39 million people by 2050. The last genuinely new class of antibiotics to reach the market did so nearly three decades ago. Since then, most approved antibiotics have been modifications of existing classes, meaning bacteria have been able to deploy pre-existing resistance mechanisms against them relatively quickly.

However, lariocidin is an early drug lead, not a clinical candidate. The research team at McMaster is currently working on ways to modify the molecule and increase its production yield. An oral or injectable formulation would require extensive chemical optimization, scale-up manufacturing, and years of Phase I through III clinical trials. The researchers acknowledge that the standard pathway from early discovery to market typically takes 10 to 15 years and requires substantial funding.

For the clinical trials sector, lariocidin represents a rare and genuine preclinical breakthrough in a discovery pipeline that has been critically underfunded relative to the scale of the AMR crisis. The identification of a completely new mechanism, validated in animal models, with a soil-to-laboratory discovery pathway that will not be replicated by synthetic chemistry alone, offers a meaningful reason for optimism in a field that has had few genuine wins at this level in a generation.

Sources: Nature (March 26, 2025, DOI: 10.1038/s41586-025-08723-7) | McMaster University Faculty of Health Sciences | C&EN (American Chemical Society) | CIDRAP | Euronews Health | WHO AMR Global Data